A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

Magnus Lindskog; Anna Laurell; Anders Kjellman; Bohuslav Melichar; Jacek Niezabitowski; Pablo Maroto; Henryk Zielinski; Felipe Villacampa; Pierre Bigot; Zoltan Bajory; Omi Parikh; David Vazquez Alba; Asa Jellvert; Tibor Flasko; Enrique Gallardo Diaz; Maria Jose Ribal; Gunta Purkalne; Peter Suenaert; Alex Karlsson-Parra; Borje Ljungberg

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

Magnus Lindskog, Anna Laurell, Anders Kjellman, Bohuslav Melichar, Jacek Niezabitowski, Pablo Maroto, Henryk Zielinski, Felipe Villacampa, Pierre Bigot, Zoltan Bajory, Omi Parikh, David Vazquez Alba, Asa Jellvert, Tibor Flasko, Enrique Gallardo Diaz, Maria Jose Ribal, Gunta Purkalne, Peter Suenaert, Alex Karlsson-Parra, Borje Ljungberg

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	11
Journal	Journal of Clinical Oncology
Volume	38
Issue number	5 Supplement
Publication status	Published - 10 Feb 2020
Externally published	Yes
Event	ASCO-SITC Clinical Immuno-Oncology Symposium - Orlando, United States Duration: 6 Feb 2020 → 8 Feb 2020 https://conferences.asco.org/immuno/archive

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.5_suppl.11

Cite this

Lindskog, M., Laurell, A., Kjellman, A., Melichar, B., Niezabitowski, J., Maroto, P., Zielinski, H., Villacampa, F., Bigot, P., Bajory, Z., Parikh, O., Alba, D. V., Jellvert, A., Flasko, T., Diaz, E. G., Ribal, M. J., Purkalne, G., Suenaert, P., Karlsson-Parra, A., & Ljungberg, B. (2020). A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma. Journal of Clinical Oncology, 38(5 Supplement), Article 11. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.5_suppl.11

@article{4160da2639034199babcd3d9a9f92b84,

title = "A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma",

author = "Magnus Lindskog and Anna Laurell and Anders Kjellman and Bohuslav Melichar and Jacek Niezabitowski and Pablo Maroto and Henryk Zielinski and Felipe Villacampa and Pierre Bigot and Zoltan Bajory and Omi Parikh and Alba, {David Vazquez} and Asa Jellvert and Tibor Flasko and Diaz, {Enrique Gallardo} and Ribal, {Maria Jose} and Gunta Purkalne and Peter Suenaert and Alex Karlsson-Parra and Borje Ljungberg",

year = "2020",

month = feb,

day = "10",

language = "English",

volume = "38",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "5 Supplement",

note = "ASCO-SITC Clinical Immuno-Oncology Symposium ; Conference date: 06-02-2020 Through 08-02-2020",

url = "https://conferences.asco.org/immuno/archive",

}

Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Niezabitowski, J, Maroto, P, Zielinski, H, Villacampa, F, Bigot, P, Bajory, Z, Parikh, O, Alba, DV, Jellvert, A, Flasko, T, Diaz, EG, Ribal, MJ, Purkalne, G, Suenaert, P, Karlsson-Parra, A & Ljungberg, B 2020, 'A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma', Journal of Clinical Oncology, vol. 38, no. 5 Supplement, 11. <https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.5_suppl.11>

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma. / Lindskog, Magnus; Laurell, Anna; Kjellman, Anders et al.
In: Journal of Clinical Oncology, Vol. 38, No. 5 Supplement, 11, 10.02.2020.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

AU - Lindskog, Magnus

AU - Laurell, Anna

AU - Kjellman, Anders

AU - Melichar, Bohuslav

AU - Niezabitowski, Jacek

AU - Maroto, Pablo

AU - Zielinski, Henryk

AU - Villacampa, Felipe

AU - Bigot, Pierre

AU - Bajory, Zoltan

AU - Parikh, Omi

AU - Alba, David Vazquez

AU - Jellvert, Asa

AU - Flasko, Tibor

AU - Diaz, Enrique Gallardo

AU - Ribal, Maria Jose

AU - Purkalne, Gunta

AU - Suenaert, Peter

AU - Karlsson-Parra, Alex

AU - Ljungberg, Borje

PY - 2020/2/10

Y1 - 2020/2/10

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000529994300016

M3 - Meeting Abstract

SN - 0732-183X

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5 Supplement

M1 - 11

T2 - ASCO-SITC Clinical Immuno-Oncology Symposium

Y2 - 6 February 2020 through 8 February 2020

ER -

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this